NATCO Pharma Management

Management criteria checks 1/4

NATCO Pharma's CEO is Rajeev Nannapaneni, appointed in Jun 2012, has a tenure of 12.67 years. directly owns 0.63% of the company’s shares, worth ₹917.06M. The average tenure of the management team and the board of directors is 5.9 years and 0.8 years respectively.

Key information

Rajeev Nannapaneni

Chief executive officer

₹98.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	12.7yrs
CEO ownership	0.6%
Management average tenure	5.9yrs
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Rajeev Nannapaneni (47 yo)

12.7yrs

Tenure

₹98,670,000

Compensation

Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Venkaiah Nannapaneni	MD & Chairman	43.4yrs	₹100.77m	25.1% ₹ 36.6b
Rajeev Nannapaneni	CEO & Vice Chairman	12.7yrs	₹98.67m	0.63% ₹ 917.1m
S. V. V. Appa Rao	Chief Financial Officer	9yrs	₹13.36m	no data
Donthineni Rao	President of Technical Affairs & Whole Time Director	no data	₹33.69m	0.030% ₹ 44.0m
Chekuri Ramesh	Company Secretary & Compliance Officer	2.8yrs	₹2.61m	no data
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	no data	₹20.16m	0.023% ₹ 33.4m
Nadella Rao	VP & Head of Operations	no data	no data	no data
N. Rao	Executive Vice President of Corporate Affairs	no data	no data	no data
James Rajakumar	Vice President of Marketing & Sales - Domestic	1.1yrs	no data	no data
A. Lakshminarayana	Senior Vice President of HR & Organisational Development	no data	no data	0.0062% ₹ 9.0m
M. Reddy	Executive Vice President of R&D	30.8yrs	no data	0.025% ₹ 35.9m
Ch. Srinivas	Senior Vice President of Demand & Supply Planning	no data	no data	no data

5.9yrs

Average Tenure

65.5yo

Average Age

Experienced Management: 524816's management team is seasoned and experienced (5.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Venkaiah Nannapaneni	MD & Chairman	43.4yrs	₹100.77m	25.1% ₹ 36.6b
Rajeev Nannapaneni	CEO & Vice Chairman	19.3yrs	₹98.67m	0.63% ₹ 917.1m
Donthineni Rao	President of Technical Affairs & Whole Time Director	10yrs	₹33.69m	0.030% ₹ 44.0m
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	10.3yrs	₹20.16m	0.023% ₹ 33.4m
Agnihotra Dakshina Chavali	Independent Director	less than a year	no data	no data
Dronadula Bhaskar	Independent Director	less than a year	no data	no data
Lakshminarayana Bolisetty	Independent Non-Executive Director	less than a year	no data	no data
Kantipudi Suma	Independent Non-Executive Director	less than a year	no data	no data
Nitin Jain	Independent Non-Executive Director	less than a year	no data	no data

0.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 524816's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/19 21:35
End of Day Share Price	2025/02/19 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NATCO Pharma Limited is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Nitin Bhasin	Ambit Capital
Prashant Nair	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

NATCO Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

NATCO Pharma Limited Announces Resignation of Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations)

Insider recently sold ₹3.5m worth of stock

Insider recently sold ₹30m worth of stock

High number of new directors

Less than half of directors are independent

NATCO Pharma Limited Announces Term Completion of Directors

Recent updates

Investor sentiment deteriorates as stock falls 33%

New minor risk - Share price stability

Price target decreased by 15% to ₹1,152

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Announces Resignation of Pavan Ganapati Bhat as Director & Executive Vice President (Technical Operations)

Lupin Limited and Natco Pharma Limited Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

NATCO Pharma Limited Announces Final Approval of Its ANDA for Bosentan Tablets for Oral Suspension (TFOS), 32Mg

Now 20% overvalued

NATCO Pharma Limited to Report Q3, 2025 Results on Feb 12, 2025

Insider recently sold ₹3.5m worth of stock

Dividend of ₹1.50 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

Price target increased by 14% to ₹1,209

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

Board Member recently sold ₹6.0m worth of stock

Investor sentiment improves as stock rises 21%

Price target increased by 9.1% to ₹1,064

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Now 22% undervalued

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹1.25 per share

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023

MD & Director recently bought ₹5.0m worth of stock

Natco Pharma Limited Announces Double Bench of the High Court of Delhi Dismiss an Appeal Filed by FMC Corporation, FMC Singapore and FMC India

Price target decreased to ₹709

Upcoming dividend of ₹0.75 per share

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2022-23, Payable from 30 November 2022

NATCO Pharma Limited to Report Q2, 2023 Results on Nov 10, 2022

Natco Pharma Limited Announces FMC Corporation and FMC Singapore Serve A Copy of Appeal on Natco